Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer

Authors: Bo Peng, Yurong Chai, Yang Li, Xinxin Liu, Jianying Zhang

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Cancerous inhibitor of PP2A (CIP2A) is a recently characterized oncoprotein, which promotes cancer cell proliferation. But the role of CIP2A in lung cancer progression is still not well understood.

Methods

The expression level of CIP2A in lung cancer tissues was examined by immunohistochemistry. CIP2A-associated cell proliferation was performed by knock down or overexpression of CIP2A in lung cancer cells. Phospho-array was used to screen kinase candidates related to expression change of CIP2A. Western-blot and luciferase reporter assay were used to validate phospho-array results.

Results

Overexpression of CIP2A in lung cancer not only triggers immune response in lung cancer patients but also promotes lung cancer cell proliferation. By phospho-array, several kinase candidates were identified, one of which is c-Jun activated kinases (JNK). The knock down of CIP2A decreased JNK phosphorylation, and the phosphorylation of downstream transcriptional factors, ATF2 and c-Jun, whose transcriptional activity were decreased as well. Furthermore, the expression level of CIP2A also affected the phosphorylation of the upstream kinase of JNK, MKK4/MKK7. At last, treatment with JNK inhibitor partially abolished CIP2A-induced cell proliferation.

Conclusion

CIP2A is a tumor-associated autoantigen in lung cancer, which promote lung cancer proliferation partially through MKK4/7-JNK signaling pathway.
Literature
1.
Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: Diagnosis and management. Am Fam Physician. 2007;75:56–63.PubMed
2.
Alberts WM. Introduction to the third edition: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:38S–40S.CrossRefPubMed
3.
4.
VanMeter AJ, Camerini S, Polci ML, Tessitore A, Trivedi N, Heiby M et al. Serum low-molecular-weight protein fractionation for biomarker discovery. Methods Mol Biol. 2012;823:237–49.
5.
6.
7.
8.
Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21:5006–15.CrossRefPubMed
9.
Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clarke RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;117:6660–8.
10.
Li N, Abe S, Kurata M, Abe-Suzuki S, Onishi I, Kirimura S et al. Over-Expression of Cancerous Inhibitor of PP2A (CIP2A) in Bone Marrow Cells from Patients with a Group of High-Risk Myelodysplastic Syndromes. Pathol. Oncol. Res. 2014; 20:399-407.
11.
Lilja L, Haapasaari KM, Bloigu R, Salonen T, Ristimaki A, Turpeenniemi-Hujanen T et al. Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma. Histopathology. 2013;63:438–9.
12.
Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol. 2012;29:113–8.
13.
Ren J, Li W, Yan L, Jiao W, Tian S, Li D, et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients’ survival. Br J Cancer. 2011;105:1905–11.
14.
Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 2012;16:1037–47.
15.
16.
Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, et al. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Med Oncol. 2013;30:406.
17.
Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 2010;29:6257–66.
18.
Chen KF, Yu HC, Liu CY, Chen HJ, Chen YC, Hou DR, et al. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Ther. 2011;10:892–901.
19.
Kim JS, Kim EJ, Oh JS, Park IC, Hwang SG. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1. Cancer Res. 2013;73:6667–78.
20.
Jeong AL, Lee S, Park JS, Han S, Jang CY, Lim JS, et al. Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity. J Biol Chem. 2014;289:28–40.
21.
Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14:152–60.CrossRefPubMed
22.
Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 2004;64:9027–34.
23.
Rivera MP, Detterbeck F, Mehta AC. Diagnosis of lung cancer: The guidelines. Chest. 2003;123:129S–36S.CrossRefPubMed
24.
Peng B, Huang X, Nakayasu ES, Petersen JR, Qiu S, Almeida IC, et al. Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis. J Proteome Res. 2013;12:1789–96.
25.
Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottazauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.
26.
Tan EM. Antinuclear antibodies: Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93–151.CrossRefPubMed
27.
Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010;10:321–8.CrossRefPubMedPubMedCentral
28.
Zhang JY, Chan EK, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 1999;189:1101–10.CrossRefPubMedPubMedCentral
29.
Looi KS, Nakayasu ES, Diaz RA, Tan EM, Almeida IC, Zhang JY. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res. 2008;7:4004–12.
30.
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.CrossRefPubMed
31.
Al-Murrani SW, Woodgett JR, Damuni Z. Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. Biochem J. 1999;341(Pt 2):293–8.CrossRefPubMedPubMedCentral
32.
Peng B, Lei N, Chai Y, Chan EK and Zhang JY. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer. Mol. Biosys. 2015; 11:105-14.
33.
Lei N, Peng B, Zhang JY. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer. Oncol Rep. 2014;32:1689–94.PubMed
Metadata
Title
CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer
Authors
Bo Peng
Yurong Chai
Yang Li
Xinxin Liu
Jianying Zhang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1899-0

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Research article

Under-treatment of elderly patients with ovarian cancer: a population based study

Research article

Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

Research article

The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study

Research article

TSG101, a tumor susceptibility gene, bidirectionally modulates cell invasion through regulating MMP-9 mRNA expression

Research article

Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits